Liquiritin inhibits MRGPRX2-mediated pseudo-allergy through the PI3K/AKT and PLCÎ³ signaling pathways.

Wang, Lu; Huang, Chuyue; Li, Zhili; Hu, Guizhou; Qi, Jin; Fan, Zhimin

Wang, Lu; Huang, Chuyue; Li, Zhili; Hu, Guizhou; Qi, Jin; Fan, Zhimin.

Afiliación

Wang L; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, PR China.
Huang C; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, PR China.
Li Z; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, PR China.
Hu G; China Pharmaceutical University, Nanjing, 211198, PR China.
Qi J; China Pharmaceutical University, Nanjing, 211198, PR China.
Fan Z; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, PR China.

Heliyon ; 9(2): e13290, 2023 Feb.

Article en En | MEDLINE | ID: mdl-36816265

Palabras clave

Anti-Pseudo-allergy; Immunopharmacology; Liquiritin; MAS-Related G protein-coupled receptor-X2; PI3K/AKT; PLCÎ³

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Heliyon Año: 2023 Tipo del documento: Article